European Vaccine Initiative (EVI)’s Post

💉 COVID-19 Vaccine Development and Distribution: The rapid development of COVID-19 vaccines marked an unprecedented achievement in global health. Vaccines based on mRNA, viral vectors, and protein subunits were developed in record time, saving millions of lives. However, equitable distribution remains a challenge, particularly in low- and middle-income countries. Logistics, manufacturing capacities, and intellectual property issues have influenced global access, underlining the importance of international cooperation for future pandemic preparedness. 🌐🔬 #VaccineInnovation #GlobalHealthEquity #PandemicPreparedness

It is quite evident that there are new methods in vaccine technology, especially in mRNA vaccines, Adenovirus vectors, and biomaterial-based platforms not seen in traditional vaccines. New technologies of this kind can contribute to solving some of the existing issues in vaccine development and distribution among people in need, which gives a rather optimistic outlook on the fight against current and potential epidemics. Read more about it on our blog: https://buff.ly/3WQ1lgt #NationalImmunizationAwarenessMonth #HIACares

🌿 Celebrating the Role of Quillaja Saponins in Advancing Vaccine Technology 🌿 Quillaja saponins continue to play a pivotal role in the development of adjuvant technology, enhancing the efficacy and safety of vaccines, particularly in the global fight against respiratory viruses like COVID-19 and influenza. At Desert King, we take pride in our long-standing history of supplying natural ingredients that have supported key initiatives in vaccine development, including efforts like the COVID-19 vaccine by Novavax. As the vaccine landscape evolves, we are excited about the potential of new partnerships and the opportunities they bring to further contribute to global health improvements. We are inspired by the collaborative spirit driving the vaccine industry forward and are committed to continuing our support for these life-saving advancements. 🔗 Explore More: https://shorturl.at/deJ56 🌐 Follow Us: Stay updated on our journey by following our LinkedIn page. #Parnership #Vaccines #GlobalHealth #Sustainability #DesertKing #Quillaja #Novavax #Sanofi

Identification of #correlatesofprotection #CoP, (immune responses associated with protection from disease), that can act as predictors of efficacy has the potential to unlock the development of safe, technically promising and potentially life-saving vaccines. Supporting research into discovery and use CoP data has the potential to improve go/no-go decision making in #clinicaldevelopment, allow rationale design of new or improved vaccines, reduce the time and cost of phase 3 testing by informing clinical trial design and provide a pathway to continue development when clinical efficacy studies are unfeasible. Coupling CoP-based approaches with post-authorisation studies to demonstrate effectiveness could lead to licensure when clinical efficacy cannot be feasibly achieved. https://lnkd.in/gdv9nwNM

How is the biotech industry fighting the mpox outbreak? 🦠 The WHO has declared a global public health emergency as cases in Africa have spiked by 160% this year. 📈 Now, Bavarian Nordic is ramping up production of the only marketed mpox vaccine Jynneos. 💉 But other vaccines are in the making to tackle shortages and boost efficacy. GeoVax Labs, Inc.’s GEO-MVA and Moderna’s mRNA vaccine aim to do so. 🏥 GeoVax’s CEO David A. Dodd told Labiotech about the company’s vaccine and how it seeks to improve vaccine production during these demanding times. 🚨 Read our latest article to find out more! 👇 https://lnkd.in/dDGe-ZMN #MpoxOutbreak #MpoxVaccine #vaccinedevelopment #biotechinnovation #globalhealth

In the most recent article: "U.S. Government to Pay Moderna $176 Million to Develop mRNA Flu Vaccine", US News discusses the "New initiative by the U.S. government to fund Moderna's efforts in developing an mRNA-based flu vaccine, reported in July 2024, highlights the growing investment in advanced vaccine technology." Experts state, “The development of mRNA vaccines for influenza aims to create more effective and quicker-to-produce vaccines. This move is part of a broader strategy to enhance pandemic preparedness and response capabilities.” Read more: https://lnkd.in/e-ckGnaB #vaccinessaveslives

On May 17: Learn how vaccine developers in the Global South brought safe, affordable, and easy-to-store COVID-19 vaccines to market—and find out how we can ensure equitable access to life-saving vaccines during future pandemics and emergencies. Register now: https://lnkd.in/egpYXpVg

Pandemic Alert: Gaps in H5N1 Vaccine Preparedness The US has only 5M H5N1 vaccines stockpiled, with production capacity of 100M doses within 5 months. No licensed mRNA flu vaccines exist, and testing capabilities are limited. As of Oct 2024, 36 human H5N1 cases were reported across 6 states. Key challenges include declining vaccine confidence, outdated production technologies, long manufacturing lead times, evolving viral strains, and distribution gaps. However, market opportunities emerge in universal flu vaccine research, novel production technologies, and innovative development platforms. Our team supports developers in overcoming these challenges, ensuring readiness for the next pandemic. Schedule a consultation today! https://lnkd.in/e33q9e3E #VaccineInnovation #PandemicPreparedness #PublicHealth #BiotechStrategy

#callforreading #recommendations in Methods and Protocols MDPI 🎉 Title: Development and Characterisation of a Four-Plex Assay to Measure Streptococcus pyogenes Antigen-Specific IgG in Human Sera ✍️ Authors: Alexander J. Keeley, Martina Carducci, Luisa Massai, Mariagrazia Pizza, Thushan I. De Silva, Danilo G. Moriel, and Omar Rossi from The University of Sheffield and GSK Vaccines Institute for Global Health 🫱 Read and Download for #free at: https://lnkd.in/g8T6-pST #methods #protocols #assay #vaccine #immunity #antibodies #IgG #humanserum

https://lnkd.in/dqurWmUz Vaccines Beat OVERCOMING IMMUNESCENESENCE - DELIVERY STRATEGIES!!! This review summarized a series of approaches to provide a reference for vaccine design for elderly individuals.